About Us
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
What we do
Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.
Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.
We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.
a future free from toxic chemo- therapy
Our goals
By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.
Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.
Our latest news
June 14, 2024
Renovaro, Inc. Announces $10 million in Equity Committed
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO.
May 24, 2024
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
This collaboration would bring together Renovaro’s proprietary cancer vaccine technology and the Cancer Center’s expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.
April 30, 2024
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
April 29, 2024
Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI
The potential impact of AI on healthcare is vast and transformative. With the use of AI platforms for diagnosing diseases like cancer, we can expect improved accuracy, efficiency, and outcomes in patient care. Renovaro stands at the forefront of this innovative shift towards a more intelligent healthcare system powered by artificial intelligence.
